{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:00:31Z","timestamp":1791928831865,"version":"4.3.4"},"reference-count":199,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"vor","delay-in-days":1054,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["5R01AG038791-09"],"award-info":[{"award-number":["5R01AG038791-09"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["K23AG059888"],"award-info":[{"award-number":["K23AG059888"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["5T32AG023481"],"award-info":[{"award-number":["5T32AG023481"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"crossref","award":["1U19AG063911-01"],"award-info":[{"award-number":["1U19AG063911-01"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100016948","name":"Tau Consortium","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016948","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS050915"],"award-info":[{"award-number":["R01NS050915"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s13311-020-00888-5","type":"journal-article","created":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T14:04:16Z","timestamp":1594908256000},"page":"1563-1581","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Four-Repeat Tauopathies: Current Management and Future Treatments"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8304-6711","authenticated-orcid":false,"given":"Lawren","family":"VandeVrede","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Ljubenkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio C.","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane E.","family":"Welch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam L.","family":"Boxer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-020-00888-5_bib1","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1146\/annurev.neuro.24.1.1121","article-title":"Neurodegenerative tauopathies","volume":"24","author":"Lee","year":"2001","journal-title":"Annu Rev Neurosci"},{"issue":"4","key":"10.1007\/s13311-020-00888-5_bib2","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/0896-6273(89)90210-9","article-title":"Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease","volume":"3","author":"Goedert","year":"1989","journal-title":"Neuron"},{"issue":"13","key":"10.1007\/s13311-020-00888-5_bib3","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1002\/j.1460-2075.1990.tb07870.x","article-title":"Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization","volume":"9","author":"Goedert","year":"1990","journal-title":"EMBO J"},{"issue":"2","key":"10.1007\/s13311-020-00888-5_bib4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1750-3639.1998.tb00162.x","article-title":"Frontotemporal dementia and Parkinsonism linked to chromosome 17: a new group of tauopathies","volume":"8","author":"Spillantini","year":"1998","journal-title":"Brain Pathol"},{"issue":"1","key":"10.1007\/s13311-020-00888-5_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/nan.12208","article-title":"Invited review: Neuropathology of tauopathies: principles and practice","volume":"41","author":"Kovacs","year":"2015","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"4","key":"10.1007\/s13311-020-00888-5_bib6","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/WCO.0b013e32833be924","article-title":"Neuropathology of variants of progressive supranuclear palsy","volume":"23","author":"Dickson","year":"2010","journal-title":"Curr Opin Neurol"},{"issue":"11","key":"10.1007\/s13311-020-00888-5_bib7","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/jnen\/61.11.935","article-title":"Office of Rare Diseases neuropathologic criteria for corticobasal degeneration","volume":"61","author":"Dickson","year":"2002","journal-title":"J Neuropathol Exp Neurol"},{"issue":"5","key":"10.1007\/s13311-020-00888-5_bib8","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","article-title":"Criteria for the diagnosis of corticobasal degeneration","volume":"80","author":"Armstrong","year":"2013","journal-title":"Neurology"},{"issue":"6","key":"10.1007\/s13311-020-00888-5_bib9","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/mds.26987","article-title":"Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria","volume":"32","author":"Hoglinger","year":"2017","journal-title":"Mov Disord"},{"issue":"18","key":"10.1007\/s13311-020-00888-5_bib10","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1212\/WNL.0000000000002638","article-title":"Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes","volume":"86","author":"Coyle-Gilchrist","year":"2016","journal-title":"Neurology"},{"issue":"11","key":"10.1007\/s13311-020-00888-5_bib11","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","article-title":"Classification of primary progressive aphasia and its variants","volume":"76","author":"Gorno-Tempini","year":"2011","journal-title":"Neurology"},{"issue":"2","key":"10.1007\/s13311-020-00888-5_bib12","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ana.22424","article-title":"Clinicopathological correlations in corticobasal degeneration","volume":"70","author":"Lee","year":"2011","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1007\/s13311-020-00888-5_bib13","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/mds.27872","article-title":"Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies","volume":"35","author":"Respondek","year":"2020","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-020-00888-5_bib14","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/bs.irn.2019.10.014","article-title":"Corticobasal degeneration","volume":"149","author":"Saranza","year":"2019","journal-title":"Int Rev Neurobiol"},{"issue":"2","key":"10.1007\/s13311-020-00888-5_bib15","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/mdc3.12582","article-title":"Is it useful to classify progressive supranuclear palsy and corticobasal degeneration as different disorders? No","volume":"5","author":"Hoglinger","year":"2018","journal-title":"Mov Disord Clin Pract"},{"key":"10.1007\/s13311-020-00888-5_bib16","doi-asserted-by":"crossref","first-page":"101644","DOI":"10.1016\/j.pneurobio.2019.101644","article-title":"Four-repeat tauopathies","volume":"180","author":"Rosler","year":"2019","journal-title":"Prog Neurobiol"},{"issue":"4","key":"10.1007\/s13311-020-00888-5_bib17","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1212\/CON.0000000000000751","article-title":"Progressive supranuclear palsy, corticobasal degeneration, and multiple system atrophy","volume":"25","author":"Greene","year":"2019","journal-title":"Continuum (Minneap Minn)"},{"issue":"4 Movement Disorders","key":"10.1007\/s13311-020-00888-5_bib18","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1212\/CON.0000000000000348","article-title":"Diagnostic approach to atypical Parkinsonian syndromes","volume":"22","author":"McFarland","year":"2016","journal-title":"Continuum (Minneap Minn)"},{"issue":"Pt 3","key":"10.1007\/s13311-020-00888-5_bib19","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.brainresbull.2016.08.018","article-title":"Tau and tauopathies","volume":"126","author":"Arendt","year":"2016","journal-title":"Brain Res Bull"},{"issue":"4","key":"10.1007\/s13311-020-00888-5_bib20","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/jnen\/60.4.393","article-title":"Substantia nigra in progressive supranuclear palsy, corticobasal degeneration, and parkinsonism-dementia complex of Guam: specific pathological features","volume":"60","author":"Oyanagi","year":"2001","journal-title":"J Neuropathol Exp Neurol"},{"issue":"Suppl 2","key":"10.1007\/s13311-020-00888-5_bib21","first-page":"II1","article-title":"Clinical features differentiating patients with postmortem confirmed progressive supranuclear palsy and corticobasal degeneration","volume":"246","author":"Litvan","year":"1999","journal-title":"J Neurol"},{"issue":"8","key":"10.1007\/s13311-020-00888-5_bib22","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1001\/archneur.55.8.1099","article-title":"Pharmacological therapy in progressive supranuclear palsy","volume":"55","author":"Kompoliti","year":"1998","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-020-00888-5_bib23","series-title":"Progressive supranuclear palsy: clinical and research approaches","article-title":"Traditional and experimental therapeutic approaches","author":"Litvan","year":"1992"},{"issue":"5","key":"10.1007\/s13311-020-00888-5_bib24","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/BF00869004","article-title":"Amantadine in parkinsonian patients unresponsive to levodopa: a pilot study","volume":"243","author":"Colosimo","year":"1996","journal-title":"J Neurol"},{"issue":"6","key":"10.1007\/s13311-020-00888-5_bib25","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2217\/nmt-2016-0027","article-title":"Managing cognition in progressive supranuclear palsy","volume":"6","author":"Rittman","year":"2016","journal-title":"Neurodegener Dis Manag"},{"issue":"9","key":"10.1007\/s13311-020-00888-5_bib26","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s40263-018-0551-3","article-title":"Therapeutic management of the overlapping syndromes of atypical parkinsonism","volume":"32","author":"Giagkou","year":"2018","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1007\/s13311-020-00888-5_bib27","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2165\/00023210-200923020-00005","article-title":"Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management","volume":"23","author":"O'Sullivan","year":"2009","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1007\/s13311-020-00888-5_bib28","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1212\/WNL.52.4.873","article-title":"Pramipexole in progressive supranuclear palsy","volume":"52","author":"Weiner","year":"1999","journal-title":"Neurology"},{"issue":"7","key":"10.1007\/s13311-020-00888-5_bib29","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/archneur.55.7.957","article-title":"Clinical presentation and pharmacological therapy in corticobasal degeneration","volume":"55","author":"Kompoliti","year":"1998","journal-title":"Arch Neurol"},{"issue":"2","key":"10.1007\/s13311-020-00888-5_bib30","doi-asserted-by":"crossref","first-page":"e0170927","DOI":"10.1371\/journal.pone.0170927","article-title":"Rehabilitation in progressive supranuclear palsy: Effectiveness of two multidisciplinary treatments","volume":"12","author":"Clerici","year":"2017","journal-title":"PLoS One"},{"issue":"12","key":"10.1007\/s13311-020-00888-5_bib31","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2165\/00002512-200118120-00003","article-title":"Progressive supranuclear palsy: clinical features, pathophysiology and management","volume":"18","author":"Rajput","year":"2001","journal-title":"Drugs Aging"},{"issue":"1","key":"10.1007\/s13311-020-00888-5_bib32","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2169\/internalmedicine.2373-18","article-title":"Management of dysphagia in patients with Parkinson's disease and related disorders","volume":"59","author":"Umemoto","year":"2020","journal-title":"Intern Med"},{"issue":"2","key":"10.1007\/s13311-020-00888-5_bib33","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3928\/0098-9134-19940201-08","article-title":"Nutritional intake. Use of touch and verbal cuing","volume":"20","author":"Lange-Alberts","year":"1994","journal-title":"J Gerontol Nurs"},{"issue":"10","key":"10.1007\/s13311-020-00888-5_bib34","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3928\/0098-9134-19951001-04","article-title":"Nursing intervention to promote functional feeding","volume":"21","author":"Van Ort","year":"1995","journal-title":"J Gerontol Nurs"},{"issue":"10","key":"10.1007\/s13311-020-00888-5_bib35","first-page":"1265","article-title":"Oropharyngeal dysphagia in neurodegenerative disease","volume":"3","author":"Walshe","year":"2014","journal-title":"J Gastroenterol Hepatol Res"},{"issue":"1","key":"10.1007\/s13311-020-00888-5_bib36","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1044\/2019_AJSLP-19-00107","article-title":"Effects of expiratory muscle strength training on videofluoroscopic measures of swallowing: a systematic review","volume":"29","author":"Mancopes","year":"2020","journal-title":"Am J Speech Lang Pathol"},{"key":"10.1007\/s13311-020-00888-5_bib37","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jns.2017.11.015","article-title":"Effect of Lee Silverman Voice Treatment (LSVT LOUD(R)) on swallowing and cough in Parkinson's disease: a pilot study","volume":"383","author":"Miles","year":"2017","journal-title":"J Neurol Sci"},{"issue":"4","key":"10.1007\/s13311-020-00888-5_bib38","first-page":"457","article-title":"Effects of neuromuscular electrical stimulation in patients with Parkinson's disease and dysphagia: a randomized, single-blind, placebo-controlled trial","volume":"42","author":"Park","year":"2018","journal-title":"NeuroRehabilitation"},{"issue":"1","key":"10.1007\/s13311-020-00888-5_bib39","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/mus.26292","article-title":"Impact of expiratory strength training in amyotrophic lateral sclerosis: results of a randomized, sham-controlled trial","volume":"59","author":"Plowman","year":"2019","journal-title":"Muscle Nerve"},{"issue":"36","key":"10.1007\/s13311-020-00888-5_bib40","doi-asserted-by":"crossref","first-page":"e8008","DOI":"10.1097\/MD.0000000000008008","article-title":"Therapeutic efficacy of neuromuscular electrical stimulation and electromyographic biofeedback on Alzheimer's disease patients with dysphagia","volume":"96","author":"Tang","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1007\/s13311-020-00888-5_bib41","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1532-5415.2010.02740.x","article-title":"Comfort feeding only: a proposal to bring clarity to decision-making regarding difficulty with eating for persons with advanced dementia","volume":"58","author":"Palecek","year":"2010","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"10.1007\/s13311-020-00888-5_bib42","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/mds.24992","article-title":"Dystonia in corticobasal degeneration: a review of the literature on 404 pathologically proven cases","volume":"27","author":"Stamelou","year":"2012","journal-title":"Mov Disord"},{"issue":"3","key":"10.1007\/s13311-020-00888-5_bib43","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s004150200009","article-title":"Botulinum toxin treatment in atypical parkinsonian disorders associated with disabling focal dystonia","volume":"249","author":"Muller","year":"2002","journal-title":"J Neurol"},{"issue":"6","key":"10.1007\/s13311-020-00888-5_bib44","doi-asserted-by":"crossref","first-page":"e01182","DOI":"10.1002\/brb3.1182","article-title":"Botulinum toxin for the treatment of dystonia and pain in corticobasal syndrome","volume":"9","author":"Unti","year":"2019","journal-title":"Brain Behav"},{"issue":"3","key":"10.1007\/s13311-020-00888-5_bib45","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s11940-013-0282-1","article-title":"Diagnosis and treatment of corticobasal degeneration","volume":"16","author":"Armstrong","year":"2014","journal-title":"Curr Treat Options Neurol"},{"issue":"Pt 5","key":"10.1007\/s13311-020-00888-5_bib46","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1093\/brain\/112.5.1171","article-title":"Corticobasal degeneration","volume":"112","author":"Gibb","year":"1989","journal-title":"Brain"},{"issue":"1","key":"10.1007\/s13311-020-00888-5_bib47","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ncl.2014.09.002","article-title":"Diagnosis and treatment of dystonia","volume":"33","author":"Jinnah","year":"2015","journal-title":"Neurol Clin"},{"issue":"15","key":"10.1007\/s13311-020-00888-5_bib48","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/mds.22608","article-title":"Paramedical treatment in primary dystonia: a systematic review","volume":"24","author":"Delnooz","year":"2009","journal-title":"Mov Disord"},{"issue":"7","key":"10.1007\/s13311-020-00888-5_bib49","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1212\/WNL.0b013e318281cc43","article-title":"Functional disturbance of the locomotor network in progressive supranuclear palsy","volume":"80","author":"Zwergal","year":"2013","journal-title":"Neurology"},{"key":"10.1007\/s13311-020-00888-5_bib50","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.parkreldis.2016.12.009","article-title":"Understanding falls in progressive supranuclear palsy","volume":"35","author":"Bluett","year":"2017","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"10.1007\/s13311-020-00888-5_bib51","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1136\/jnnp.2005.074070","article-title":"Predictors of falls and fractures in bradykinetic rigid syndromes: a retrospective study","volume":"77","author":"Williams","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1007\/s13311-020-00888-5_bib52","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/ptj\/82.5.485","article-title":"Supported treadmill training for gait and balance in a patient with progressive supranuclear palsy","volume":"82","author":"Suteerawattananon","year":"2002","journal-title":"Phys Ther"},{"issue":"5","key":"10.1007\/s13311-020-00888-5_bib53","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/0003-9993(93)90120-Y","article-title":"Progressive supranuclear palsy: clinical presentation and rehabilitation of two patients","volume":"74","author":"Sosner","year":"1993","journal-title":"Arch Phys Med Rehabil"},{"issue":"1058","key":"10.1007\/s13311-020-00888-5_bib54","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/mds.26256","article-title":"In-patient multidisciplinary rehabilitation for Parkinson's disease: a randomized controlled trial","volume":"30","author":"Monticone","year":"2015","journal-title":"Mov Disord"},{"issue":"6","key":"10.1007\/s13311-020-00888-5_bib55","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1107911","article-title":"Tai chi and postural stability in patients with Parkinson's disease","volume":"366","author":"Li","year":"2012","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1007\/s13311-020-00888-5_bib56","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s40520-017-0836-2","article-title":"Effects of dance practice on functional mobility, motor symptoms and quality of life in people with Parkinson's disease: a systematic review with meta-analysis","volume":"30","author":"Dos Santos Delabary","year":"2018","journal-title":"Aging Clin Exp Res"},{"issue":"1","key":"10.1007\/s13311-020-00888-5_bib57","first-page":"8","article-title":"Feldenkrais method-based exercise improves quality of life in individuals with Parkinson's disease: a controlled, randomized clinical trial","volume":"21","author":"Teixeira-Machado","year":"2015","journal-title":"Altern Ther Health Med"},{"issue":"1","key":"10.1007\/s13311-020-00888-5_bib58","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2522\/ptj.20100142","article-title":"Boxing training for patients with Parkinson disease: a case series","volume":"91","author":"Combs","year":"2011","journal-title":"Phys Ther"},{"issue":"1-2","key":"10.1007\/s13311-020-00888-5_bib59","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3109\/00207459808986437","article-title":"Transcranial AC pulsed applications of weak electromagnetic fields reduces freezing and falling in progressive supranuclear palsy: a case report","volume":"94","author":"Sandyk","year":"1998","journal-title":"Int J Neurosci"},{"issue":"8","key":"10.1007\/s13311-020-00888-5_bib60","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1212\/WNL.41.8.1298","article-title":"Occurrence of resting tremor in Parkinson's disease","volume":"41","author":"Rajput","year":"1991","journal-title":"Neurology"},{"issue":"1","key":"10.1007\/s13311-020-00888-5_bib61","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1212\/WNL.48.1.119","article-title":"Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study","volume":"48","author":"Litvan","year":"1997","journal-title":"Neurology"},{"issue":"8","key":"10.1007\/s13311-020-00888-5_bib62","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1002\/mds.23612","article-title":"Cortical origin of myoclonus in early stages of corticobasal degeneration","volume":"26","author":"Notturno","year":"2011","journal-title":"Mov Disord"},{"issue":"Suppl 1","key":"10.1007\/s13311-020-00888-5_bib63","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1016\/j.parkreldis.2015.09.023","article-title":"Therapeutic interventions in parkinsonism: corticobasal degeneration","volume":"22","author":"Marsili","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"10.1007\/s13311-020-00888-5_bib64","doi-asserted-by":"crossref","first-page":"28","DOI":"10.14802\/jmd.14007","article-title":"Suppression of myoclonus in corticobasal degeneration by levetiracetam","volume":"7","author":"Cho","year":"2014","journal-title":"J Mov Disord"},{"issue":"2","key":"10.1007\/s13311-020-00888-5_bib65","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/archneur.58.2.265","article-title":"Neuropathological correlates of dysarthria in progressive supranuclear palsy","volume":"58","author":"Kluin","year":"2001","journal-title":"Arch Neurol"},{"issue":"3 Pt 1","key":"10.1007\/s13311-020-00888-5_bib66","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1212\/WNL.43.3_Part_1.563","article-title":"Perceptual analysis of speech disorders in progressive supranuclear palsy","volume":"43","author":"Kluin","year":"1993","journal-title":"Neurology"},{"issue":"4","key":"10.1007\/s13311-020-00888-5_bib67","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1007\/s00415-015-7671-1","article-title":"Speech disorders reflect differing pathophysiology in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy","volume":"262","author":"Rusz","year":"2015","journal-title":"J Neurol"},{"issue":"6","key":"10.1007\/s13311-020-00888-5_bib68","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jvoice.2010.01.002","article-title":"Acoustical analysis of speech in progressive supranuclear palsy","volume":"25","author":"Skodda","year":"2011","journal-title":"J Voice"},{"issue":"1","key":"10.1007\/s13311-020-00888-5_bib69","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1046\/j.1468-1331.2003.00545.x","article-title":"Yes\/no reversals as neurobehavioral sequela: a disorder of language, praxis, or inhibitory control?","volume":"10","author":"Frattali","year":"2003","journal-title":"Eur J Neurol"},{"key":"10.1007\/s13311-020-00888-5_bib70","doi-asserted-by":"crossref","unstructured":"Peterson, K.A., K. Patterson, and J.B. Rowe, Language impairment in progressive supranuclear palsy and corticobasal syndrome. J Neurol, 2019.","DOI":"10.1007\/s00415-019-09463-1"},{"issue":"2","key":"10.1007\/s13311-020-00888-5_bib71","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1136\/practneurol-2018-001921","article-title":"Speech and language therapy approaches to managing primary progressive aphasia","volume":"20","author":"Volkmer","year":"2020","journal-title":"Pract Neurol"},{"issue":"1","key":"10.1007\/s13311-020-00888-5_bib72","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1044\/0161-1461(2006\/006)","article-title":"Family members' perceptions of augmentative and alternative communication device use","volume":"37","author":"Bailey","year":"2006","journal-title":"Lang Speech Hear Serv Sch"},{"issue":"1","key":"10.1007\/s13311-020-00888-5_bib73","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1749-818X.2008.00112.x","article-title":"Speaking and hearing clearly: talker and listener factors in speaking style changes","volume":"3","author":"Smiljanic","year":"2009","journal-title":"Lang Linguist Compass"},{"issue":"3","key":"10.1007\/s13311-020-00888-5_bib74","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1159\/000287209","article-title":"Effect of rate control on speech production and intelligibility in dysarthria","volume":"62","author":"Van Nuffelen","year":"2010","journal-title":"Folia Phoniatr Logop"},{"key":"10.1007\/s13311-020-00888-5_bib75","first-page":"xi","article-title":"Evidence for effectiveness of treatment of loudness, rate, or prosody in dysarthria: a systematic review","volume":"15","author":"Yorkston","year":"2007","journal-title":"J Med Speech Lang Pathol"},{"issue":"5","key":"10.1007\/s13311-020-00888-5_bib76","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/0269215517734385","article-title":"Lee Silverman Voice Treatment (LSVT)-BIG to improve motor function in people with Parkinson's disease: a systematic review and meta-analysis","volume":"32","author":"McDonnell","year":"2018","journal-title":"Clin Rehabil"},{"key":"10.1007\/s13311-020-00888-5_bib77","first-page":"483","article-title":"Pseudobulbar affect: prevalence and management","volume":"9","author":"Ahmed","year":"2013","journal-title":"Ther Clin Risk Manag"},{"key":"10.1007\/s13311-020-00888-5_bib78","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12883-016-0609-0","article-title":"PRISM II: an open-label study to assess effectiveness of dextromethorphan\/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury","volume":"16","author":"Hammond","year":"2016","journal-title":"BMC Neurol"},{"issue":"3","key":"10.1007\/s13311-020-00888-5_bib79","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s13311-016-0508-5","article-title":"Enhanced bulbar function in amyotrophic lateral sclerosis: The Nuedexta Treatment Trial","volume":"14","author":"Smith","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"5","key":"10.1007\/s13311-020-00888-5_bib80","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/ana.22093","article-title":"Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect","volume":"68","author":"Pioro","year":"2010","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1007\/s13311-020-00888-5_bib81","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/ana.410360112","article-title":"Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy","volume":"36","author":"Litvan","year":"1994","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-020-00888-5_bib82","first-page":"CD004900","article-title":"Botulinum toxin type A therapy for blepharospasm","volume":"1","author":"Costa","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1007\/s13311-020-00888-5_bib83","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/mds.870090605","article-title":"\u201cApraxia of lid opening,\u201d a focal eyelid dystonia: clinical study of 32 patients","volume":"9","author":"Krack","year":"1994","journal-title":"Mov Disord"},{"issue":"7","key":"10.1007\/s13311-020-00888-5_bib84","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJM199908123410721","article-title":"Zolpidem in progressive supranuclear palsy","volume":"341","author":"Daniele","year":"1999","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1007\/s13311-020-00888-5_bib85","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jocn.2009.05.038","article-title":"The use of zolpidem in the treatment of progressive supranuclear palsy","volume":"17","author":"Cotter","year":"2010","journal-title":"J Clin Neurosci"},{"key":"10.1007\/s13311-020-00888-5_bib86","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1212\/01.CON.0000466658.05156.54","article-title":"Executive dysfunction","volume":"21","author":"Rabinovici","year":"2015","journal-title":"Continuum (Minneap Minn)"},{"issue":"3","key":"10.1007\/s13311-020-00888-5_bib87","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/gps.4245","article-title":"Target risk factors for dementia prevention: a systematic review and Delphi consensus study on the evidence from observational studies","volume":"30","author":"Deckers","year":"2015","journal-title":"Int J Geriatr Psychiatry"},{"issue":"3","key":"10.1007\/s13311-020-00888-5_bib88","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1055\/s-0038-1660786","article-title":"A life participation approach to primary progressive aphasia intervention","volume":"39","author":"Rogalski","year":"2018","journal-title":"Semin Speech Lang"},{"issue":"2","key":"10.1007\/s13311-020-00888-5_bib89","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.bandl.2013.05.018","article-title":"Examining the value of lexical retrieval treatment in primary progressive aphasia: two positive cases","volume":"127","author":"Henry","year":"2013","journal-title":"Brain Lang"},{"issue":"8","key":"10.1007\/s13311-020-00888-5_bib90","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s11940-015-0362-5","article-title":"Treatment of primary progressive aphasia","volume":"17","author":"Tippett","year":"2015","journal-title":"Curr Treat Options Neurol"},{"issue":"6","key":"10.1007\/s13311-020-00888-5_bib91","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1093\/gerona\/gly264","article-title":"Multiple sensory impairment is associated with increased risk of dementia among black and white older adults","volume":"74","author":"Brenowitz","year":"2019","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"5","key":"10.1007\/s13311-020-00888-5_bib92","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/MAO.0000000000000313","article-title":"Relationship of hearing loss and dementia: a prospective, population-based study","volume":"35","author":"Gurgel","year":"2014","journal-title":"Otol Neurotol"},{"issue":"6","key":"10.1007\/s13311-020-00888-5_bib93","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/brain\/awy101","article-title":"Retraining speech production and fluency in non-fluent\/agrammatic primary progressive aphasia","volume":"141","author":"Henry","year":"2018","journal-title":"Brain"},{"issue":"1-2","key":"10.1007\/s13311-020-00888-5_bib94","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1155\/2013\/824302","article-title":"Treatment for apraxia of speech in nonfluent variant primary progressive aphasia","volume":"26","author":"Henry","year":"2013","journal-title":"Behav Neurol"},{"key":"10.1007\/s13311-020-00888-5_bib95","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2147\/CIA.S178878","article-title":"Investigating the utility of teletherapy in individuals with primary progressive aphasia","volume":"14","author":"Dial","year":"2019","journal-title":"Clin Interv Aging"},{"key":"10.1007\/s13311-020-00888-5_bib96","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.neuropsychologia.2019.02.022","article-title":"Improved language production with transcranial direct current stimulation in progressive supranuclear palsy","volume":"127","author":"Madden","year":"2019","journal-title":"Neuropsychologia"},{"issue":"4","key":"10.1007\/s13311-020-00888-5_bib97","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3233\/JAD-131427","article-title":"Treatment of primary progressive aphasias by transcranial direct current stimulation combined with language training","volume":"39","author":"Cotelli","year":"2014","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"10.1007\/s13311-020-00888-5_bib98","first-page":"69","article-title":"Supporting communication for patients with neurodegenerative disease","volume":"37","author":"Fried-Oken","year":"2015","journal-title":"NeuroRehabilitation"},{"issue":"9","key":"10.1007\/s13311-020-00888-5_bib99","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1080\/02687039808249575","article-title":"Supported conversation for adults with aphasia: methods and resources for training conversation partners","volume":"12","author":"Kagan","year":"1998","journal-title":"Aphasiology"},{"issue":"Pt 2","key":"10.1007\/s13311-020-00888-5_bib100","first-page":"239","article-title":"Cholinergic systems in progressive supranuclear palsy","volume":"128","author":"Warren","year":"2005","journal-title":"Brain"},{"issue":"3","key":"10.1007\/s13311-020-00888-5_bib101","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1212\/WNL.57.3.467","article-title":"Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy","volume":"57","author":"Litvan","year":"2001","journal-title":"Neurology"},{"issue":"2","key":"10.1007\/s13311-020-00888-5_bib102","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1447-0594.2012.00956.x","article-title":"Pilot study of pharmacological treatment for frontotemporal dementia: risk of donepezil treatment for behavioral and psychological symptoms","volume":"13","author":"Kimura","year":"2013","journal-title":"Geriatr Gerontol Int"},{"issue":"1","key":"10.1007\/s13311-020-00888-5_bib103","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/01.JGP.0000231744.69631.33","article-title":"Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia","volume":"15","author":"Mendez","year":"2007","journal-title":"Am J Geriatr Psychiatry"},{"issue":"2","key":"10.1007\/s13311-020-00888-5_bib104","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1474-4422(12)70320-4","article-title":"Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial","volume":"12","author":"Boxer","year":"2013","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1007\/s13311-020-00888-5_bib105","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3233\/JAD-2010-101632","article-title":"Memantine in behavioral variant frontotemporal dementia: negative results","volume":"23","author":"Vercelletto","year":"2011","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"10.1007\/s13311-020-00888-5_bib106","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/WAD.0b013e3181cf468d","article-title":"Pilot trial of memantine in primary progressive aphasia","volume":"24","author":"Johnson","year":"2010","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"1-2","key":"10.1007\/s13311-020-00888-5_bib107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000439521","article-title":"Behavioral evolution of progressive semantic aphasia in comparison with nonfluent aphasia","volume":"41","author":"Gomez-Tortosa","year":"2016","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"Pt 9","key":"10.1007\/s13311-020-00888-5_bib108","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1093\/brain\/awr179","article-title":"Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia","volume":"134","author":"Rascovsky","year":"2011","journal-title":"Brain"},{"issue":"5","key":"10.1007\/s13311-020-00888-5_bib109","doi-asserted-by":"crossref","first-page":"212","DOI":"10.4088\/JCP.v58n0506","article-title":"Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors","volume":"58","author":"Swartz","year":"1997","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"10.1007\/s13311-020-00888-5_bib110","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s004010000293","article-title":"Frontotemporal dementia: evidence for impairment of ascending serotoninergic but not noradrenergic innervation. Immunocytochemical and quantitative study using a graph method","volume":"101","author":"Yang","year":"2001","journal-title":"Acta Neuropathol"},{"issue":"4","key":"10.1007\/s13311-020-00888-5_bib111","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/jgs.12730","article-title":"Detroit Expert Panel on Assessment and Management of Neuropsychiatric Symptoms of Dementia, Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel","volume":"62","author":"Kales","year":"2014","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"10.1007\/s13311-020-00888-5_bib112","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/09638288.2017.1387614","article-title":"The tailored activity program (TAP) to address behavioral disturbances in frontotemporal dementia: a feasibility and pilot study","volume":"41","author":"O'Connor","year":"2019","journal-title":"Disabil Rehabil"},{"issue":"3","key":"10.1007\/s13311-020-00888-5_bib113","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.psychres.2013.08.045","article-title":"Behavioral abnormalities in progressive supranuclear palsy","volume":"210","author":"Gerstenecker","year":"2013","journal-title":"Psychiatry Res"},{"issue":"6","key":"10.1007\/s13311-020-00888-5_bib114","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1192\/bjp.bp.113.141119","article-title":"Non-pharmacological interventions for agitation in dementia: systematic review of randomised controlled trials","volume":"205","author":"Livingston","year":"2014","journal-title":"Br J Psychiatry"},{"issue":"7","key":"10.1007\/s13311-020-00888-5_bib115","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1001\/jama.2014.93","article-title":"Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial","volume":"311","author":"Porsteinsson","year":"2014","journal-title":"JAMA"},{"issue":"15","key":"10.1007\/s13311-020-00888-5_bib116","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa061240","article-title":"Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease","volume":"355","author":"Schneider","year":"2006","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1007\/s13311-020-00888-5_bib117","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1111\/j.1468-1331.2012.03784.x","article-title":"EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia","volume":"19","author":"Sorbi","year":"2012","journal-title":"Eur J Neurol"},{"issue":"2-3","key":"10.1007\/s13311-020-00888-5_bib118","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0014-2999(02)02557-8","article-title":"Comparison of the anticholinergic effects of the serotonergic antidepressants, paroxetine, fluvoxamine and clomipramine","volume":"454","author":"Fujishiro","year":"2002","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"10.1007\/s13311-020-00888-5_bib119","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/j.1532-5415.1997.tb02984.x","article-title":"Nortriptyline for the treatment of depression in progressive supranuclear palsy","volume":"45","author":"Tamai","year":"1997","journal-title":"J Am Geriatr Soc"},{"issue":"8","key":"10.1007\/s13311-020-00888-5_bib120","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1212\/WNL.35.8.1189","article-title":"Treatment of progressive supranuclear palsy with tricyclic antidepressants","volume":"35","author":"Newman","year":"1985","journal-title":"Neurology"},{"issue":"1","key":"10.1007\/s13311-020-00888-5_bib121","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/00124509-200103000-00015","article-title":"Electroconvulsive therapy-responsive depression in a patient with progressive supranuclear palsy","volume":"17","author":"Netzel","year":"2001","journal-title":"J ECT"},{"key":"10.1007\/s13311-020-00888-5_bib122","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0072-9752(07)01249-3","article-title":"Current and future management of the corticobasal syndrome and corticobasal degeneration","volume":"89","author":"Boeve","year":"2008","journal-title":"Handb Clin Neurol"},{"issue":"7","key":"10.1007\/s13311-020-00888-5_bib123","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1001\/jamaneurol.2019.0534","article-title":"Effects of mindfulness yoga vs stretching and resistance training exercises on anxiety and depression for people with Parkinson disease: a randomized clinical trial","volume":"76","author":"Kwok","year":"2019","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1007\/s13311-020-00888-5_bib124","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1176\/appi.ajp.2017.17030316","article-title":"Methylphenidate for apathy in community-dwelling older veterans with mild Alzheimer's disease: a double-blind, randomized, placebo-controlled trial","volume":"175","author":"Padala","year":"2018","journal-title":"Am J Psychiatry"},{"issue":"8","key":"10.1007\/s13311-020-00888-5_bib125","doi-asserted-by":"crossref","first-page":"810","DOI":"10.4088\/JCP.12m08099","article-title":"Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial","volume":"74","author":"Rosenberg","year":"2013","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"10.1007\/s13311-020-00888-5_bib126","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/JCP.0b013e318172b479","article-title":"Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge","volume":"28","author":"Herrmann","year":"2008","journal-title":"J Clin Psychopharmacol"},{"issue":"10","key":"10.1007\/s13311-020-00888-5_bib127","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.jalz.2019.06.3916","article-title":"Profound degeneration of wake-promoting neurons in Alzheimer's disease","volume":"15","author":"Oh","year":"2019","journal-title":"Alzheimers Dement"},{"key":"10.1007\/s13311-020-00888-5_bib128","doi-asserted-by":"crossref","unstructured":"Walsh, C.M., L. Ruoff, K. Walker, et al., Sleepless night and day, the plight of progressive supranuclear palsy. Sleep, 2017. 40(11).","DOI":"10.1093\/sleep\/zsx154"},{"issue":"4","key":"10.1007\/s13311-020-00888-5_bib129","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.sleep.2008.05.004","article-title":"Polysomnographic findings, video-based sleep analysis and sleep perception in progressive supranuclear palsy","volume":"10","author":"Sixel-Doring","year":"2009","journal-title":"Sleep Med"},{"issue":"2","key":"10.1007\/s13311-020-00888-5_bib130","doi-asserted-by":"crossref","first-page":"e0149278","DOI":"10.1371\/journal.pone.0149278","article-title":"Urinary dysfunction in progressive supranuclear palsy compared with other parkinsonian disorders","volume":"11","author":"Yamamoto","year":"2016","journal-title":"PLoS One"},{"key":"10.1007\/s13311-020-00888-5_bib131","doi-asserted-by":"crossref","unstructured":"Coupland, C.A.C., T. Hill, T. Dening, R. Morriss, M. Moore, and J. Hippisley-Cox, Anticholinergic drug exposure and the risk of dementia: a nested case-control study. JAMA Intern Med, 2019.","DOI":"10.1001\/jamainternmed.2019.0677"},{"issue":"3","key":"10.1007\/s13311-020-00888-5_bib132","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.eururo.2005.05.015","article-title":"A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial","volume":"48","author":"Chapple","year":"2005","journal-title":"Eur Urol"},{"issue":"1","key":"10.1007\/s13311-020-00888-5_bib133","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12877-020-1474-7","article-title":"Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR)","volume":"20","author":"Griebling","year":"2020","journal-title":"BMC Geriatr"},{"issue":"5-6","key":"10.1007\/s13311-020-00888-5_bib134","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1159\/000095750","article-title":"Caregiver burden, health-related quality of life and coping in dementia caregivers: a comparison of frontotemporal dementia and Alzheimer's disease","volume":"22","author":"Riedijk","year":"2006","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"3","key":"10.1007\/s13311-020-00888-5_bib135","first-page":"60","article-title":"Progressive supranuclear palsy: managing the disabilities and providing nursing support","volume":"17","author":"Rohs","year":"1996","journal-title":"Axone"},{"issue":"10","key":"10.1007\/s13311-020-00888-5_bib136","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jalz.2016.06.006","article-title":"Therapeutic strategies for the treatment of tauopathies: hopes and challenges","volume":"12","author":"Khanna","year":"2016","journal-title":"Alzheimers Dement"},{"issue":"5","key":"10.1007\/s13311-020-00888-5_bib137","doi-asserted-by":"crossref","first-page":"e266","DOI":"10.1212\/NXI.0000000000000266","article-title":"CoQ10 in progressive supranuclear palsy: a randomized, placebo-controlled, double-blind trial","volume":"3","author":"Apetauerova","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"Pt 1","key":"10.1007\/s13311-020-00888-5_bib138","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/brain\/awn291","article-title":"Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study","volume":"132","author":"Bensimon","year":"2009","journal-title":"Brain"},{"issue":"8","key":"10.1007\/s13311-020-00888-5_bib139","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1007\/s00415-016-8169-1","article-title":"PROSPERA: a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy","volume":"263","author":"Nuebling","year":"2016","journal-title":"J Neurol"},{"key":"10.1007\/s13311-020-00888-5_bib140","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.clineuro.2016.04.021","article-title":"Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy","volume":"146","author":"Leclair-Visonneau","year":"2016","journal-title":"Clin Neurol Neurosurg"},{"issue":"4","key":"10.1007\/s13311-020-00888-5_bib141","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/mds.25824","article-title":"A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy","volume":"29","author":"Tolosa","year":"2014","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-020-00888-5_bib142","doi-asserted-by":"crossref","unstructured":"VandeVrede L, Marian L Dale, Fields S, Frank M, Hare E, Heuer HW, Keith K, Koestler M, Ljubenkov PA, McDermott D, Ohanesian N, Richards J, Rojas JC, Thijssen EH, Walsh C, Wang P, Wolf P, Quinn JF, Tsai R, Boxer AL, Open-label phase 1 futility studies of salsalate and young plasma in progressive supranuclear palsy. Movement Disorders Clinical Practice (in press), 2020.","DOI":"10.1002\/mdc3.12940"},{"key":"10.1007\/s13311-020-00888-5_bib143","unstructured":"Pharmaceuticals, T., TRX-237 phase 3 clinical trial update. 2016."},{"issue":"7","key":"10.1007\/s13311-020-00888-5_bib144","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S1474-4422(14)70088-2","article-title":"Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2\/3 trial","volume":"13","author":"Boxer","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-020-00888-5_bib145","doi-asserted-by":"crossref","unstructured":"Tsai, R.M., Z. Miller, M. Koestler, et al., Reactions to multiple ascending doses of the microtubule stabilizer TPI-287 in patients with Alzheimer disease, progressive supranuclear palsy, and corticobasal syndrome: a randomized clinical trial. JAMA Neurol, 2019.","DOI":"10.1001\/jamaneurol.2019.3812"},{"issue":"6","key":"10.1007\/s13311-020-00888-5_bib146","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1474-4422(19)30139-5","article-title":"Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial","volume":"18","author":"Boxer","year":"2019","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1007\/s13311-020-00888-5_bib147","first-page":"236","article-title":"Preclinical and clinical development of ABBV-8E12, a humanized anti-tau antibody, for treatment of Alzheimer's disease and other tauopathies","volume":"4","author":"West","year":"2017","journal-title":"J Prev Alzheimers Dis"},{"issue":"4","key":"10.1007\/s13311-020-00888-5_bib148","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1023\/B:JOBB.0000041772.74810.92","article-title":"Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment","volume":"36","author":"Beal","year":"2004","journal-title":"J Bioenerg Biomembr"},{"issue":"1","key":"10.1007\/s13311-020-00888-5_bib149","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1006\/exnr.2000.7607","article-title":"Further evidence for mitochondrial dysfunction in progressive supranuclear palsy","volume":"168","author":"Albers","year":"2001","journal-title":"Exp Neurol"},{"issue":"7","key":"10.1007\/s13311-020-00888-5_bib150","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/mds.22023","article-title":"Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial","volume":"23","author":"Stamelou","year":"2008","journal-title":"Mov Disord"},{"issue":"7","key":"10.1007\/s13311-020-00888-5_bib151","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/21678707.2017.1335596","article-title":"Therapeutic options for progressive supranuclear palsy including investigational drugs","volume":"5","author":"Shoeibi","year":"2017","journal-title":"Expert Opinion on Orphan Drugs"},{"key":"10.1007\/s13311-020-00888-5_bib152","doi-asserted-by":"crossref","unstructured":"Miller, R.G., J.D. Mitchell, M. Lyon, and D.H. Moore, Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND). Cochrane Database Syst Rev, 2007(1): p. CD001447.","DOI":"10.1002\/14651858.CD001447.pub2"},{"issue":"6","key":"10.1007\/s13311-020-00888-5_bib153","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1586\/ern.13.60","article-title":"Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms","volume":"13","author":"Naoi","year":"2013","journal-title":"Expert Rev Neurother"},{"issue":"3","key":"10.1007\/s13311-020-00888-5_bib154","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/1097-4547(20001101)62:3<463::AID-JNR16>3.0.CO;2-7","article-title":"Phosphorylation of human tau protein by microtubule-associated kinases: GSK3beta and cdk5 are key participants","volume":"62","author":"Flaherty","year":"2000","journal-title":"J Neurosci Res"},{"issue":"15","key":"10.1007\/s13311-020-00888-5_bib155","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1007\/s00018-007-7045-7","article-title":"Glycogen synthase kinase 3: a key regulator of cellular fate","volume":"64","author":"Forde","year":"2007","journal-title":"Cell Mol Life Sci"},{"issue":"19","key":"10.1007\/s13311-020-00888-5_bib156","doi-asserted-by":"crossref","first-page":"6990","DOI":"10.1073\/pnas.0500466102","article-title":"Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo","volume":"102","author":"Noble","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1007\/s13311-020-00888-5_bib157","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1046\/j.1471-4159.2000.0721327.x","article-title":"The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3","volume":"72","author":"Chen","year":"1999","journal-title":"J Neurochem"},{"issue":"6","key":"10.1007\/s13311-020-00888-5_bib158","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1021\/jm011020u","article-title":"First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease","volume":"45","author":"Martinez","year":"2002","journal-title":"J Med Chem"},{"issue":"4","key":"10.1007\/s13311-020-00888-5_bib159","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/13543784.2018.1460356","article-title":"Preclinical, phase I, and phase II investigational clinical trials for treatment of progressive supranuclear palsy","volume":"27","author":"Shoeibi","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"issue":"29","key":"10.1007\/s13311-020-00888-5_bib160","doi-asserted-by":"crossref","first-page":"10804","DOI":"10.1073\/pnas.0400348101","article-title":"O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease","volume":"101","author":"Liu","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Pt 7","key":"10.1007\/s13311-020-00888-5_bib161","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1093\/brain\/awp099","article-title":"Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease","volume":"132","author":"Liu","year":"2009","journal-title":"Brain"},{"issue":"7","key":"10.1007\/s13311-020-00888-5_bib162","first-page":"P261","article-title":"Early clinical results and preclinical validation of the O-GlcNAcase (OGA) inhibitor MK-8719 as a novel therapeutic for the treatment of tauopathies","volume":"12","author":"Smith","year":"2016","journal-title":"Alzheimer's & Dementia: the journal of the Alzheimer's Association"},{"key":"10.1007\/s13311-020-00888-5_bib163","unstructured":"Therapeutics, A., Alectos Therapeutics announces FDA orphan drug designation for MK-8719: an investigational small-molecule OGA inhibitor for treatment of progressive supranuclear palsy. 2016."},{"issue":"7","key":"10.1007\/s13311-020-00888-5_bib164","first-page":"P227","article-title":"Pharmacological intervention with the novel o-glcnacase inhibitor ASN-561 reduces pathological tau in transgenic mice","volume":"11","author":"Permanne","year":"2015","journal-title":"Alzheimer's & dementia: the journal of the Alzheimer's Association"},{"issue":"7","key":"10.1007\/s13311-020-00888-5_bib165","first-page":"P251","article-title":"Phase 1 study in healthy volunteers of the O-glcnacase inhibitor ASN120290 as a novel therapy for progressive supranuclear palsy and related tauopathies","volume":"14","author":"Ryan","year":"2018","journal-title":"Alzheimer's Dementia"},{"issue":"6184","key":"10.1007\/s13311-020-00888-5_bib166","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1126\/science.1251141","article-title":"Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors","volume":"344","author":"Katsimpardi","year":"2014","journal-title":"Science"},{"issue":"6","key":"10.1007\/s13311-020-00888-5_bib167","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/nm.3569","article-title":"Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice","volume":"20","author":"Villeda","year":"2014","journal-title":"Nat Med"},{"issue":"11","key":"10.1007\/s13311-020-00888-5_bib168","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/jamaneurol.2016.3185","article-title":"Preclinical assessment of young blood plasma for Alzheimer disease","volume":"73","author":"Middeldorp","year":"2016","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1007\/s13311-020-00888-5_bib169","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.neuron.2010.08.044","article-title":"Acetylation of tau inhibits its degradation and contributes to tauopathy","volume":"67","author":"Min","year":"2010","journal-title":"Neuron"},{"issue":"10","key":"10.1007\/s13311-020-00888-5_bib170","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/nm.3951","article-title":"Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits","volume":"21","author":"Min","year":"2015","journal-title":"Nat Med"},{"issue":"20","key":"10.1007\/s13311-020-00888-5_bib171","doi-asserted-by":"crossref","first-page":"11213","DOI":"10.1073\/pnas.93.20.11213","article-title":"Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines","volume":"93","author":"Wischik","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-020-00888-5_bib172","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40478-015-0204-4","article-title":"Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau","volume":"3","author":"Hochgrafe","year":"2015","journal-title":"Acta Neuropathol Commun"},{"issue":"14","key":"10.1007\/s13311-020-00888-5_bib173","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1093\/hmg\/ddu080","article-title":"Methylene blue upregulates Nrf2\/ARE genes and prevents tau-related neurotoxicity","volume":"23","author":"Stack","year":"2014","journal-title":"Hum Mol Genet"},{"issue":"10062","key":"10.1007\/s13311-020-00888-5_bib174","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1016\/S0140-6736(16)31275-2","article-title":"Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial","volume":"388","author":"Gauthier","year":"2016","journal-title":"Lancet"},{"key":"10.1007\/s13311-020-00888-5_bib175","doi-asserted-by":"crossref","unstructured":"Medina, M., An Overview on the clinical development of tau-based therapeutics. Int J Mol Sci, 2018. 19(4).","DOI":"10.3390\/ijms19041160"},{"key":"10.1007\/s13311-020-00888-5_bib176","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1749-6632.1999.tb07884.x","article-title":"A novel signaling molecule for neuropeptide action: activity-dependent neuroprotective protein","volume":"897","author":"Gozes","year":"1999","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"10.1007\/s13311-020-00888-5_bib177","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1124\/jpet.107.130526","article-title":"A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease","volume":"325","author":"Matsuoka","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1007\/s13311-020-00888-5_bib178","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.nbd.2009.02.011","article-title":"NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model","volume":"34","author":"Shiryaev","year":"2009","journal-title":"Neurobiol Dis"},{"issue":"10","key":"10.1007\/s13311-020-00888-5_bib179","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1001\/archneur.63.10.1459","article-title":"Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein","volume":"63","author":"Rosenmann","year":"2006","journal-title":"Arch Neurol"},{"issue":"2","key":"10.1007\/s13311-020-00888-5_bib180","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nrn3887","article-title":"Spreading of pathology in neurodegenerative diseases: a focus on human studies","volume":"16","author":"Brettschneider","year":"2015","journal-title":"Nat Rev Neurosci"},{"issue":"4","key":"10.1007\/s13311-020-00888-5_bib181","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/alzrt277","article-title":"Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer's disease","volume":"6","author":"Kontsekova","year":"2014","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.1007\/s13311-020-00888-5_bib182","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13195-018-0436-1","article-title":"FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease","volume":"10","author":"Novak","year":"2018","journal-title":"Alzheimers Res Ther"},{"issue":"2","key":"10.1007\/s13311-020-00888-5_bib183","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S1474-4422(16)30331-3","article-title":"Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"16","author":"Novak","year":"2017","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1007\/s13311-020-00888-5_bib184","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.neurobiolaging.2014.09.007","article-title":"Human secreted tau increases amyloid-beta production","volume":"36","author":"Bright","year":"2015","journal-title":"Neurobiol Aging"},{"issue":"3","key":"10.1007\/s13311-020-00888-5_bib185","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/acn3.176","article-title":"Anti-tau antibody reduces insoluble tau and decreases brain atrophy","volume":"2","author":"Yanamandra","year":"2015","journal-title":"Ann Clin Transl Neurol"},{"issue":"2","key":"10.1007\/s13311-020-00888-5_bib186","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.neuron.2013.07.046","article-title":"Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition vivo","volume":"80","author":"Yanamandra","year":"2013","journal-title":"Neuron"},{"issue":"386","key":"10.1007\/s13311-020-00888-5_bib187","doi-asserted-by":"crossref","first-page":"eaal2029","DOI":"10.1126\/scitranslmed.aal2029","article-title":"Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy","volume":"9","author":"Yanamandra","year":"2017","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1007\/s13311-020-00888-5_bib188","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s00401-018-1911-2","article-title":"Epitope determines efficacy of therapeutic anti-Tau antibodies in a functional assay with human Alzheimer Tau","volume":"136","author":"Courade","year":"2018","journal-title":"Acta Neuropathol"},{"issue":"6","key":"10.1007\/s13311-020-00888-5_bib189","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.neurobiolaging.2012.12.003","article-title":"Age-appropriate cognition and subtle dopamine-independent motor deficits in aged tau knockout mice","volume":"34","author":"Morris","year":"2013","journal-title":"Neurobiol Aging"},{"issue":"2","key":"10.1007\/s13311-020-00888-5_bib190","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/jnc.12960","article-title":"Tolfenamic acid reduces tau and CDK5 levels: implications for dementia and tauopathies","volume":"133","author":"Adwan","year":"2015","journal-title":"J Neurochem"},{"issue":"18","key":"10.1007\/s13311-020-00888-5_bib191","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-020-00888-5_bib192","unstructured":"Ionis Pharmaceuticals, I., IONIS-HTT Rx (RG6042) Top-line data demonstrate significant reductions of disease-causing mutant huntingtin protein in people with Huntington's disease. 2018."},{"issue":"374","key":"10.1007\/s13311-020-00888-5_bib193","doi-asserted-by":"crossref","first-page":"eaag0481","DOI":"10.1126\/scitranslmed.aag0481","article-title":"Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy","volume":"9","author":"DeVos","year":"2017","journal-title":"Sci Transl Med"},{"issue":"7","key":"10.1007\/s13311-020-00888-5_bib194","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S1474-4422(17)30157-6","article-title":"Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches","volume":"16","author":"Boxer","year":"2017","journal-title":"Lancet Neurol"},{"issue":"Pt 6","key":"10.1007\/s13311-020-00888-5_bib195","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1093\/brain\/awm032","article-title":"A clinical rating scale for progressive supranuclear palsy","volume":"130","author":"Golbe","year":"2007","journal-title":"Brain"},{"key":"10.1007\/s13311-020-00888-5_bib196","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.parkreldis.2016.04.014","article-title":"Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials","volume":"28","author":"Bang","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"10.1007\/s13311-020-00888-5_bib197","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/13803395.2019.1572073","article-title":"Cognitive deficits in progressive supranuclear palsy on the Repeatable Battery for the Assessment of Neuropsychological Status","volume":"41","author":"Duff","year":"2019","journal-title":"J Clin Exp Neuropsychol"},{"issue":"4","key":"10.1007\/s13311-020-00888-5_bib198","doi-asserted-by":"crossref","first-page":"e273","DOI":"10.1212\/WNL.0000000000004859","article-title":"CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP","volume":"90","author":"Rojas","year":"2018","journal-title":"Neurology"},{"issue":"1","key":"10.1007\/s13311-020-00888-5_bib199","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13195-019-0470-7","article-title":"(18)F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes","volume":"11","author":"Tsai","year":"2019","journal-title":"Alzheimers Res Ther"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-020-00888-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-020-00888-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792301259X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792301259X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-020-00888-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:02:39Z","timestamp":1761807759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187874792301259X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":199,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S187874792301259X"],"URL":"https:\/\/doi.org\/10.1007\/s13311-020-00888-5","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Four-Repeat Tauopathies: Current Management and Future Treatments","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-020-00888-5","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}